Drug development panel discussed how the technological advancements in Big Data, Machine Learning and Cloud Computing, when paired with focus on combination therapies that include for instance, anti cancer and immuno oncology agents, or paired with next gen sequencing technologies, and advanced companion diagnostics, with relentless focus on patient outcomes, may open new frontiers in cost effective drug development.
Drug development panel was moderated by Dr. Suneel Gupta, Chief Scientific Officer at Impax Pharmaceuticals. Gupta has over 25 years experience in pharmaceutical R&D, specifically around drug delivery technologies. Gupta shared the story of how Impax launched RYTARY, an extended-release oral capsule formulation drug, for the treatment of Parkinson’s disease, and took it in a span of 3.5 years, with $100M, from benchmark to launch. This is Impax’s first branded drug internally developed and approved for commercialization and it was achieved with “relentless execution”, said Gupta. Gupta’s advice to…
View original post 743 more words
DRUG REGULATORY AFFAIRS INTERNATIONAL 